Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: An update and implications for clinicians

Pharmacogenomics

Volumn 15, Issue 8, 2014, Pages 1147-1157

  Zai, Gwyneth ^a,b,c,d   Brandl, Eva J ^a,b   Müller, Daniel J ^a,b,c   Richter, Margaret A ^b,c,d   Kennedy, James L ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

antidepressant drug treatment response; cytochrome P450 drug metabolism system; genetics; obsessive compulsive and related disorders; obsessive compulsive disorder; OCD; pharmacogenetics

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; ANTIDEPRESSANT AGENT; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; EXCITATORY AMINO ACID TRANSPORTER 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

COMT GENE; CONTROLLED STUDY; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; CYP3A4 GENE; CYP450 GENE; DISEASE ASSOCIATION; DLGAP2 GENE; DRD2 GENE; DRD4 GENE; DRUG METABOLISM; DRUG RESPONSE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GRIN2B GENE; HTR1B GENE; HTR2A GENE; HTR2C GENE; HTTLPR GENE; HUMAN; MAJOR DEPRESSION; MAOA GENE; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PHARMACOGENETICS; REVIEW; SLC1A1 GENE; SLC6A4 GENE; TPH GENE; DRUG INACTIVATION; GENETICS; OBSESSIVE-COMPULSIVE DISORDER; PATHOLOGY;

ANTIDEPRESSIVE AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INACTIVATION, METABOLIC; OBSESSIVE-COMPULSIVE DISORDER; PHARMACOGENETICS; SEROTONIN UPTAKE INHIBITORS;

EID: 84905442231     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.83     Document Type: Review

References (71)

1. Tiwari AK, Souza RP, Muller DJ. Pharmacogenetics of anxiolytic drugs. J. Neural Transm. 116(6), 667-677 (2009).
2. Brandl EJ, Muller DJ, Richter MA. Pharmacogenetics of obsessive-compulsive disorders. Pharmacogenomics 13(1), 71-81 (2012).
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (5th Edition). American Psychiatric Association, VA, USA (2013).
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (4th Edition, Text Revision). American Psychiatric Association, VA, USA (2000).
5. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol. Psychiatry 15(1), 53-63 (2010).
6. Monzani B, Rijsdijk F, Harris J, Mataix-Cols D. The structure of genetic and environmental risk factors for dimensional representations of DSM-5 obsessive- compulsive spectrum disorders. JAMA Psychiatry 71(2), 182-189 (2014).
7. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectr. 19(1), 50-61 (2014).
8. Pauls DL. The genetics of obsessive-compulsive disorder: a review. Dialogues Clin. Neurosci. 12(2), 149-163 (2010).
9. Van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. Twin Res. Hum. Genet. 8(5), 450-458 (2005).
10. Mathews CA, Nievergelt CM, Azzam A et al. Heritability and clinical features of multigenerational families with obsessive-compulsive disorder and hoarding. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B(2), 174-182 (2007).
11. Novak CE, Keuthen NJ, Stewart SE, Pauls DL. A twin concordance study of trichotillomania. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B(7), 944-949 (2009).
12. Monzani B, Rijsdijk F, Cherkas L, Harris J, Keuthen N, Mataix-Cols D. Prevalence and heritability of skin picking in an adult community sample: a twin study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B(5), 605-610 (2012).
13. Monzani B, Rijsdijk F, Anson M et al. A twin study of body dysmorphic concerns. Psychol. Med. 42(9), 1949-1955 (2012).
14. Saxena S. Pharmacotherapy of compulsive hoarding. J. Clin. Psychol. 67(5), 477-484 (2011).
15. Mathews CA, Badner JA, Andresen JM et al. Genome-wide linkage analysis of obsessive-compulsive disorder implicates chromosome 1p36. Biol. Psychiatry 72(8), 629-636 (2012).
16. Ross J, Badner J, Garrido H et al. Genomewide linkage analysis in Costa Rican families implicates chromosome 15q14 as a candidate region for OCD. Hum. Genet. 130(6), 795-805 (2011).
17. Taylor S. Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. Mol. Psychiatry 18(7), 799-805 (2013).
18. Stewart SE, Yu D, Scharf JM et al. Genome-wide association study of obsessive-compulsive disorder. Mol. Psychiatry 18(7), 788-798 (2013).
19. Stewart SE, Mayerfeld C, Arnold PD et al. Meta-analysis of association between obsessive-compulsive disorder and the 3′ region of neuronal glutamate transporter gene SLC1A1. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B(4), 367-379 (2013).
20. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. Arch. Gen. Psychiatry 63(7), 769-776 (2006).
21. Grados MA, Specht MW, Sung HM, Fortune D. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach. Expert Opin. Drug Discov. 8(12), 1515-1527 (2013).
22. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology 174(4), 530-538 (2004).
23. Fabbri C, Di Girolamo G, Serretti A. Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162B(6), 487-520 (2013).
24. GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 170(2), 207-217 (2013).
25. Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 45, 183-194 (2013).
26. Singh AB, Bousman CA, Ng C, Berk M. Antidepressant pharmacogenetics. Curr. Opin. Psychiatry 27(1), 43-51 (2014).
27. Altar CA, Hornberger J, Shewade A, Cruz V, Garrison J, Mrazek D. Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. Int. Rev. Psychiatry 25(5), 509-533 (2013).
28. Weizman S, Gonda X, Dome P, Faludi G. Pharmacogenetics of antidepressive drugs: a way towards personalized treatment of major depressive disorder. Neuropsychopharmacol. Hung. 14(2), 87-101 (2012).
29. Müller DJ, Brandl EJ, Hwang R et al. The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. Genet. Test. Mol. Biomarkers 16(8), 897-903 (2012).
30. Brandl EJ, Tiwari AK, Zhou X et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 14(2), 176-181 (2014).
31. Vulink NC, Westenberg HG, Van Nieuwerburgh F et al. Catechol-O- methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder. Int. J. Psychiatry Clin. Pract. 16(4), 277-283 (2012).
32. Corregiari FM, Bernik M, Cordeiro Q, Vallada H. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder. Clinics 67(4), 335-340 (2012).
33. Viswanath B, Taj MJR, Purushottam M et al. No association between DRD4 gene and SRI treatment response in obsessive compulsive disorder: need for a novel approach. Asian J. Psychiatry 6(4), 347-348 (2013).
34. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can. J. Psychiatry 51(8 Suppl. 2), 9S-91S (2006).
35. Zai G, Brandl E, Deluce J, Kennedy JL, Richter MA. Pharmacogenetics of twelve candidate genes and antidepressant response in obsessive-compulsive disorder. Presented at: 12th Annual Pharmacogenetics in Psychiatry Meeting. FL, USA, 31 May-1 June 2013.
36. Wu PL, Tang HS, Lane HY, Tsai CA, Tsai GE. Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study. J. Clin. Psychopharmacol. 31(3), 369-374 (2011).
37. Caley CF. Interpreting and applying CYP450 genomic test results to psychotropic medications. J. Pharm. Pract. 24(5), 439-446 (2011).
38. Flockhart DA. Drug interactions: cytochrome P450 drug interaction table (2007). http://medicine.iupui.edu/clinpharm/ddis/clinical-table/
39. Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93(5), 402-408 (2013).
40. Jann MW, Cohen LJ. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metab. Drug Interact. 16(1), 39-67 (2000).
41. Neafsey P, Ginsberg G, Hattis D, Sonawane B. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): population distribution of CYP2D6 activity. J. Toxicol. Environ. Health B Crit Rev. 12(5-6), 334-361 (2009).
42. Bernard S, Neville KA, Nguyen AT, Flockhart DA. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11(2), 126-135 (2006).
43. Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41(12), 913-958 (2002).
44. Gvozdic K, Brandl EJ, Taylor DL, Muller DJ. Genetics and personalized medicine in antidepressant treatment. Curr. Pharm. Des. 18(36), 5853-5878 (2012).
45. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am. J. Psychiatry 164(7 Suppl.), 5-53 (2007).
46. Zai G, Zai CC, Goncalves V et al. Pharmacogenetics of obsessive-compulsive disorder candidate genes and their regulatory regions in antidepressant response. Presented at: 52nd Annual Meeting of the American College of Neuropsychopharmacology. FL, USA, 8-12 December 2013.
47. Nair A, Howard R. ENCODE and a new landscape for psychiatric genetics. Br. J. Psychiatry 203(2), 84-85 (2013).
48. Kariuki-Nyuthe C, Gomez-Mancilla B, Stein DJ. Obsessive compulsive disorder and the glutamatergic system. Curr. Opin. Psychiatry 27(1), 32-37 (2014).
49. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol. Biochem. Behav. 100(4), 726-735 (2012).
50. Milad MR, Rauch SL. Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways. Trends Cogn. Sci. 16(1), 43-51 (2012).
51. Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, Bullmore ET. Integrating evidence from neuroimaging and neuropsychological studies of obsessive- compulsive disorder: the orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev. 32(3), 525-549 (2008).
52. Qin H-D, Wang Y, Grados MA et al. Whole genome association study identified novel antidepressant response loci for the treatment of obsessive-compulsive disorder with selective sertonin re-uptake inhibitors. Presented at: 52nd Annual Meeting of the American College of Neuropsychopharmacology. FL, USA, 8-12 December 2013.
53. Allen NJ, Bennett ML, Foo LC et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature 486(7403), 410-414 (2012).
54. Real E, Gratacos M, Alonso P et al. Pharmacological resistance level in OCD patients without a stressful life event at onset of the disorder is associated with a polymorphism of the glutamate transporter gene (SLC1A1). Presented at: 18th World Congress of Psychiatric Genetics. Athens, Greece, 3-7 October 2010.
55. Koo MS, Kim EJ, Roh D, Kim CH. Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. Expert Rev. Neurother. 10(2), 275-290 (2010).
56. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. Int. J. Neuropsychopharmacol. 16(3), 557-574 (2013).
57. Autry AE, Monteggia LM. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64(2), 238-258 (2012).
58. Real E, Gratacos M, Soria V et al. A brain-derived neurotrophic factor haplotype is associated with therapeutic response in obsessive-compulsive disorder. Biol. Psychiatry 66(7), 674-680 (2009).
59. Zai G, Bezchlibnyk YB, Richter MA et al. Myelin oligodendrocyte glycoprotein (MOG) gene is associated with obsessive-compulsive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 129B(1), 64-68 (2004).
60. Stewart SE, Platko J, Fagerness J et al. A genetic family-based association study of OLIG2 in obsessive-compulsive disorder. Arch. Gen. Psychiatry 64(2), 209-214 (2007).
61. Zai G, Sicard T, Burroughs E, Kennedy JL, Richter MA. An exploration of the oligodendrocyte lineage transcription factor 2 gene and obsessive-compulsive disorder. Psychiatr. Genet. 22(3), 149 (2012).
62. Matsui A, Tran M, Yoshida AC et al. BTBD3 controls dendrite orientation toward active axons in mammalian neocortex. Science 342(6162), 1114-1118 (2013).
63. Perez-Torrado R, Yamada D, Defossez PA. Born to bind: the BTB protein-protein interaction domain. BioEssays 28(12), 1194-1202 (2006).
64. Riviere JB, Xiong L, Levchenko A et al. Association of intronic variants of the BTBD9 gene with Tourette syndrome. Arch. Neurol. 66(10), 1267-1272 (2009).
65. Roessler E, Ma Y, Ouspenskaia MV et al. Truncating loss-of-function mutations of DISP1 contribute to holoprosencephaly-like microform features in humans. Hum. Genet. 125(4), 393-400 (2009).
66. Shaffer LG, Theisen A, Bejjani BA et al. The discovery of microdeletion syndromes in the post-genomic era: review of the methodology and characterization of a new 1q41q42 microdeletion syndrome. Genet. Med. 9(9), 607-616 (2007).
67. Redies C, Hertel N, Hubner CA. Cadherins and neuropsychiatric disorders. Brain Res. 1470, 130-144 (2012).
68. Mack NA, Porter AP, Whalley HJ et al. beta2-syntrophin and Par-3 promote an apicobasal Rac activity gradient at cell-cell junctions by differentially regulating Tiam1 activity. Nature Cell Biol. 14(11), 1169-1180 (2012).
69. Liu J, Li G, Peng X et al. The cloning and preliminarily functional analysis of the human neurotrimin gene. Sci. China C Life Sci. 47(2), 158-164 (2004).
70. ENCODE Project Consortium, Bernstein BE, Birney E et al. An integrated encyclopedia of DNA elements in the human genome. Nature 489(7414), 57-74 (2012).
71. Kavanagh DH, Dwyer S, O'Donovan MC, Owen MJ. The ENCODE project: implications for psychiatric genetics. Mol. Psychiatry 18(5), 540-542 (2013).